Spinal Cord Injury (SCI) Clinical Trial Monitor

The spinal cord injury clinical trial landscape in 2026

Spinal cord injury affects approximately 300,000 people in the United States, with 17,000 new injuries annually. Despite decades of preclinical promise, no pharmacological treatment has achieved robust Phase 3 success for neurological recovery. The pipeline in 2026 reflects the field's evolution toward combination approaches, precision patient selection, and technology-assisted recovery.

The most active development areas in SCI combine neuroprotection in the acute injury phase with regenerative or rehabilitative approaches in the chronic phase. Electrical stimulation — particularly epidural spinal stimulation — has demonstrated compelling results in restoring voluntary movement in chronic SCI and is the subject of multiple ongoing trials. Meanwhile, cell-based therapies and antibody approaches targeting inhibitory signals in the injured cord continue advancing through early-phase trials.

• Neuroprotection (acute): Riluzole, minocycline, and novel agents targeting secondary injury cascades in the acute phase (0–72 hours post-injury)
• Anti-inhibitory approaches: Antibodies and small molecules blocking myelin-associated inhibitors (Nogo, MAG, OMgp) to promote axon regeneration
• Epidural electrical stimulation: Multiple trials testing whether sustained stimulation can restore voluntary movement and autonomic function in chronic SCI
• Cell therapy: Schwann cells, mesenchymal stem cells, and oligodendrocyte progenitors being tested in Phase 1/2 trials
• Exoskeleton and robotics: Device-assisted rehabilitation trials testing activity-dependent plasticity
• Autonomic and bladder function: Therapies targeting bowel, bladder, and cardiovascular autonomic complications — often the highest patient priority

Who uses spinal cord injury trial monitoring

Neuro pharma and med-tech BD teams

Companies developing neuroprotection agents, biologics targeting axon regeneration, or electrical stimulation devices use SCI trial monitoring to track competitive programs and identify partnering opportunities. The intersection of pharmacology and device therapy in SCI creates unique BD opportunities for companies spanning both categories.

SCI foundation and research organizations

Organizations like the Christopher & Dana Reeve Foundation, Unite 2 Fight Paralysis, and Wings for Life monitor the full trial pipeline to coordinate funding strategy, connect patients with trials, and identify the most promising programs for advocacy and support.

Rehabilitation technology investors

The exoskeleton and epidural stimulation space has attracted significant venture capital. Investors tracking Wandercraft, Ekso Bionics, and stimulation device developers need real-time visibility into trial registrations and Phase 2/3 progress.

Current SCI trial activity (as of March 2026)

Phase	Recruiting Trials	Key Sponsors
Phase 3	1	Industry sponsor
Phase 2	6	VA Research, Washington University, Spaulding Rehabilitation
Phase 1 / Phase 1–2	10	Academic medical centers, device companies
Total recruiting	76	Academic, VA, and industry programs

Frequently asked questions

How current is the SCI trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track acute vs. chronic SCI trials separately?

Yes. Use "acute spinal cord injury" or "chronic spinal cord injury" as watchlist keywords to focus on the specific disease stage most relevant to your programs.

Does DataLookout cover device and rehabilitation trials in SCI?

Yes. ClinicalTrials.gov includes device trials, stimulation therapies, and rehabilitation technology studies alongside pharmacological programs.

How is DataLookout different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic email notifications without phase filtering or organized digests. DataLookout delivers a structured daily summary designed for professional pipeline monitoring.